NYSE:TARO - New York Stock Exchange, Inc. - IL0010827181 - Common Stock - Currency: USD
42.97
0 (0%)
The current stock price of TARO is 42.97 USD. In the past month the price increased by 0.44%. In the past year, price increased by 10.83%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. The firm operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The firm markets over 200 pharmaceutical products in over 25 countries. The firm's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The firm's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
TARO PHARMACEUTICAL INDUS
14 Hakitor Street, PO Box 10347
Haifa 10532 IL
CEO: Uday Baldota
Employees: 1554
Company Website: https://www.taro.com/
Phone: 97248475700
The current stock price of TARO is 42.97 USD.
The exchange symbol of TARO PHARMACEUTICAL INDUS is TARO and it is listed on the New York Stock Exchange, Inc. exchange.
TARO stock is listed on the New York Stock Exchange, Inc. exchange.
6 analysts have analysed TARO and the average price target is 43.86 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 42.97. Check the TARO PHARMACEUTICAL INDUS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TARO PHARMACEUTICAL INDUS (TARO) has a market capitalization of 1.61B USD. This makes TARO a Small Cap stock.
TARO PHARMACEUTICAL INDUS (TARO) currently has 1554 employees.
TARO PHARMACEUTICAL INDUS (TARO) has a support level at 42.8 and a resistance level at 43.11. Check the full technical report for a detailed analysis of TARO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TARO does not pay a dividend.
TARO PHARMACEUTICAL INDUS (TARO) will report earnings on 2024-07-24, after the market close.
The PE ratio for TARO PHARMACEUTICAL INDUS (TARO) is 24.98. This is based on the reported non-GAAP earnings per share of 1.72 and the current share price of 42.97 USD. Check the full fundamental report for a full analysis of the valuation metrics for TARO.
ChartMill assigns a technical rating of 6 / 10 to TARO. When comparing the yearly performance of all stocks, TARO turns out to be only a medium performer in the overall market: it outperformed 68.84% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to TARO. TARO has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months TARO reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS increased by 156.72% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 8.55% | ||
ROA | 2.49% | ||
ROE | 3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to TARO. The Buy consensus is the average rating of analysts ratings from 6 analysts.